Results 91 to 100 of about 17,823 (170)

The Anti-Proliferative and Pro-apoptotic Effect of Topotecan in Combination With Thymoquinone in Acute Myelogenous Leukemia

, 2016
Topotecan (a novel topoisomerase I inhibitor and a water-soluble camptothecin analog) is active against numerous human tumor cell lines, and has shown promising antineoplastic activity in solid tumors and acute leukemia.
Tarras, Omayr, Rizk, Sandra, Khalife, Rana   +2 more
core   +1 more source

Cellular Basis of Antiproliferative and Antitumor Activity of the Novel Camptothecin Derivative, Gimatecan, in Bladder Carcinoma Models

Neoplasia: An International Journal for Oncology Research, 2005
To investigate the cellular/molecular basis of the activity of a novel lipophilic camptothecin, gimatecan (ST1481), against slowly proliferating cells, we performed a comparative study of topotecan and gimatecan in human bladder cancer models (HT1376 and
Paola Ulivi, Wainer Zoli, Francesco Fabbri, Giovanni Brigliadori, Luca Ricotti, Anna Tesei, Marco Rosetti, Michelandrea De Cesare, Giovanni L. Beretta, Elisabetta Corna, Rosanna Supino, Franco Zunino   +11 more
doaj   +1 more source

Combined effect of topotecan and irradiation on the survival and the induction of chromosome aberrations in vitro

, 2002
Background: Topotecan demonstrated radiosensitizing effects in vivo and in vitro, which are schedule- and cell Line dependent. The underlying mechanisms are not fully understood.
Glomme, S., Virsik-Koepp, Patricia, Hertig, J., Weiss, Elisabeth, Pradier, Olivier, Schmidberger, Heinz, Rave-Fraenk, Margret, Hess, C. F.   +7 more
core   +1 more source

Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment

Diagnostics
Background: Small-cell lung cancer (SCLC) is a highly aggressive tumor, and overall survival (OS) remains poor despite intensive efforts to develop new treatment strategies.
Laura Lambrecht, Paola Arnold, Jürgen Behr, Pontus Mertsch, Amanda Tufman, Diego Kauffmann-Guerrero   +5 more
doaj   +1 more source

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis

, 2004
The aim of this study was to characterise the pharmacokinetics of the anticancer agent topotecan, and explore the influence of patient covariates and interoccasion variability on drug disposition.
J Verweij, Bugat, R, A Sparreboom, M Goffinet, R H J Mathijssen, R Bugat, Verweij, Jaap, Loos, Walter, J Fourcade, E Chatelut, F Léger, Goffinet, M, Mathijssen, RHJ; id_orcid, Léger, F, Sparreboom, A, W J Loos, Fourcade, J, Chatelut, E   +17 more
core   +1 more source

Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.

, 1996
PURPOSE To determine the maximum-tolerated systemic exposure (MTSE) and exposure-limiting toxicity of continuous infusion topotecan in children with recurrent acute leukemia.
W E Evans, C B Pratt, S D Baker, W L Furman, C F Stewart, G K Rivera   +5 more
core   +1 more source

Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside

OncoImmunology, 2018
Despite recent advances in high-risk neuroblastoma therapy, the prognosis for patients remains poor. In addition, many patients suffer from complications related to available therapies that are highly detrimental to their quality of life.
S. Faraj, M. Bahri, S. Fougeray, A. El Roz, J. Fleurence, J. Véziers, M. D. Leclair, E. Thébaud, F. Paris, S. Birklé   +9 more
doaj   +1 more source

Phase I and pharmacologic study of topotecan in patients with impaired renal function.

, 1996
PURPOSE To determine the toxicities, pharmacokinetics, and recommended doses of the topoisomerase I inhibitor, topotecan, in patients with varying degrees of renal excretory dysfunction.
A A Forastiere, S O'Reilly, T L Chen, L B Grochow, D S Ettinger, S Sartorius, E K Rowinsky, W Slichenmyer, R C Donehower   +8 more
core   +1 more source

Suprachoroidal Injection of Topotecan for Retinoblastoma: A Preclinical Study

Ophthalmology Science
Purpose: To assess whether levels of topotecan that are expected to be therapeutic against retinoblastoma tumors can be achieved within the retina and choroid by suprachoroidal injection (SCI) and to assess toxicity and safety in vivo.
Arun D. Singh, MD, Vishal Raval, MD, Sandeep Kumar, PhD, Anthony Daniels, MD   +3 more
doaj   +1 more source

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

, 1999
PURPOSE: Topotecan and cyclophosphamide, doxorubicin, and vincristine (CAV) were evaluated in a randomized, multicenter study of patients with small-cell lung cancer (SCLC) who had relapsed at least 60 days after completion of first-line therapy ...
J.P. Kleisbauer, David J. Stewart, Jacqueline B. Krebs, Peter I. Clark, Martin C. Palmer, Frances A. Shepherd, Joan H. Schiller, Graham Ross, Alain Depierre, Stephen R. Lane, Joachim von Pawel, Scott Z. Fields, James Carmichael, Nick G. Chrysson, Richard Gralla   +14 more
core   +1 more source